Last Updated: November 16, 2026

Litigation Details for Novartis Pharmaceuticals Corporation v. Par Pharmaceutical, Inc. (D. Del. 2015)

« Back to Dashboard


Novartis Pharmaceuticals Corporation v. Par Pharmaceutical, Inc. (D. Del. 2015)

Docket 1:15-cv-00475 Date Filed 2015-06-10
Court District Court, D. Delaware Date Terminated 2015-10-15
Cause 35:271 Patent Infringement Assigned To Richard Gibson Andrews
Jury Demand None Referred To
Patents 9,006,224
Link to Docket External link to docket
Small Molecule Drugs cited in Novartis Pharmaceuticals Corporation v. Par Pharmaceutical, Inc.
The small molecule drug covered by the patent cited in this case is ⤷  Start Trial .

Details for Novartis Pharmaceuticals Corporation v. Par Pharmaceutical, Inc. (D. Del. 2015)

Date Filed Document No. Description Snippet Link To Document
2015-06-10 External link to document
2015-06-10 17 the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,006,224. (Attachments: # 1 …2015 15 October 2015 1:15-cv-00475 830 Patent None District Court, D. Delaware External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Novartis v. Par Pharmaceutical, 1:15-cv-00475: Gilenya Patent Litigation Analysis

Last updated: August 15, 2026

Novartis Pharmaceuticals Corporation sued Par Pharmaceutical, Inc. in the U.S. District Court for the District of Delaware after Par filed an abbreviated new drug application seeking approval to market generic fingolimod, the active ingredient in Gilenya. The litigation centered on U.S. Patent No. 9,187,405, which claimed methods of treating multiple sclerosis with a daily 0.5 mg dose of fingolimod.

The case became part of broader Gilenya generic-entry litigation involving several ANDA applicants. The Federal Circuit ultimately affirmed the district court’s judgment in Novartis’s favor, preserving the asserted patent against Par’s challenge. The decision delayed Par’s ability to launch an approved generic version of Gilenya based on the challenged ANDA while the patent remained enforceable. (Novartis Pharmaceuticals Corp. v. Par Pharmaceutical, Inc., 38 F.4th 1333 (Fed. Cir. 2022)).

What drug and patent were at issue in Novartis v. Par?

The case involved Gilenya, a multiple sclerosis treatment containing fingolimod hydrochloride.

Item Detail
Brand drug Gilenya
Active ingredient Fingolimod hydrochloride
Therapeutic area Relapsing forms of multiple sclerosis
Innovator Novartis Pharmaceuticals Corporation
ANDA challenger Par Pharmaceutical, Inc.
Court U.S. District Court for the District of Delaware
Civil action No. 1:15-cv-00475
Central patent U.S. Patent No. 9,187,405
Federal Circuit decision 38 F.4th 1333
Regulatory pathway ANDA with Paragraph IV certification
Core dispute Infringement, written description, enablement and validity of a fingolimod dosing method

The asserted patent covered the use of fingolimod at a 0.5 mg daily dose for treating multiple sclerosis. The dosing limitation was commercially significant because 0.5 mg became the standard Gilenya dose for adult patients.

What patents protect Gilenya and fingolimod?

The Gilenya patent estate has included composition, formulation, treatment-method and dosing patents. The asserted patent in the Par litigation was the method-of-treatment patent that protected the 0.5 mg daily regimen.

U.S. Patent No. 9,187,405

The '405 patent is directed to methods of treating multiple sclerosis using fingolimod. The litigation focused on whether the patent adequately described and enabled the claimed 0.5 mg daily treatment regimen.

The principal legal issues were:

  1. Whether the specification provided written-description support for the claimed dose.
  2. Whether a skilled artisan could practice the claimed treatment without undue experimentation.
  3. Whether Par’s ANDA product and proposed labeling would infringe.
  4. Whether the claims were invalid under the Patent Act.

The Federal Circuit treated the claimed dosing regimen as a specific therapeutic method rather than an unprotected statement of a desired clinical result. The court’s decision preserved the patent claims against Par’s invalidity challenge. (38 F.4th at 1333).

Other Gilenya-related protection

Gilenya’s broader protection has included earlier patents covering fingolimod compounds and pharmaceutical compositions. Those patents have had different expiration dates and legal significance. A generic applicant may avoid an expired composition patent yet remain blocked by a later-expiring method-of-use or dosing patent if its ANDA labeling induces infringement.

The commercial exposure therefore depended on the combined Orange Book listing, the scope of each claim, pediatric exclusivity, any applicable patent-term adjustment and the applicant’s Paragraph IV strategy.

When did the Novartis v. Par Gilenya litigation begin?

Novartis filed the Delaware action in 2015 after receiving notice of Par’s Paragraph IV certification. The filing triggered the Hatch-Waxman litigation framework and imposed an automatic 30-month stay on FDA approval of Par’s ANDA, subject to statutory exceptions and court orders. (21 U.S.C. § 355(j)(5)(B)(iii)).

The case proceeded through claim construction, fact and expert discovery, dispositive motion practice and trial-level adjudication. The asserted patent issued after the initial filing of the action, creating a procedural issue common in ANDA cases: the complaint may begin with earlier patent rights, while the litigation later includes a newly issued patent covering the same commercial product or therapeutic use.

Key procedural sequence

Period Event
2015 Novartis filed the Delaware action against Par
2015 onward Par challenged the asserted Gilenya patent through the ANDA litigation process
District court phase The parties litigated infringement and validity, including written description and enablement
2022 Federal Circuit issued its decision in Novartis’s favor
Post-appeal The decision maintained the asserted patent’s force against Par’s challenge

The action was one of several related Gilenya patent cases filed against ANDA applicants. The outcome had relevance beyond Par because the same patent estate was asserted against other generic manufacturers.

What was Par’s Paragraph IV challenge?

Par’s ANDA included a Paragraph IV certification asserting that the relevant Novartis patent was invalid, unenforceable or would not be infringed by the proposed generic product.

A Paragraph IV certification creates a litigation event because the ANDA applicant must notify the patent holder and the listed patent owner. The patent holder may then sue within 45 days to obtain the statutory approval stay. A Paragraph IV case does not itself establish that the generic product is unlawful. It shifts the dispute into federal court before FDA approval.

Par’s challenge placed the following issues before the court:

  • Whether the claims adequately supported the 0.5 mg fingolimod dose.
  • Whether the claimed method was enabled across the scope of the claims.
  • Whether Par’s proposed generic labeling encouraged performance of the patented method.
  • Whether the asserted claims were otherwise invalid.
  • Whether the ANDA product created an artificial controversy before commercial launch.

What did the Federal Circuit decide?

The Federal Circuit affirmed the district court’s judgment in Novartis’s favor. The appellate decision left the asserted Gilenya patent intact against Par.

The decision addressed the relationship between the patent specification and the claimed fingolimod dose. Par argued that the patent did not adequately describe the specific 0.5 mg regimen and that the claims were not enabled. The Federal Circuit rejected Par’s challenge and upheld the district court’s treatment of the asserted claims.

Written-description analysis

Written description requires the patent specification to demonstrate that the inventor possessed the claimed invention as of the relevant filing date. For a pharmaceutical method claim, the analysis can focus on whether the specification identifies the claimed compound, disease and dosage regimen with sufficient technical specificity.

The dispute was not resolved by asking whether a skilled artisan could later discover that 0.5 mg worked. The relevant question was whether the patent disclosure supported possession of the claimed treatment method when the application was filed.

The appellate ruling supported Novartis’s position that the specification adequately disclosed the claimed fingolimod regimen.

Enablement analysis

Enablement asks whether the patent teaches a skilled artisan how to make and use the claimed invention without undue experimentation. In drug patent cases, enablement may be contested where the claims cover a broad patient population, multiple disease states or a range of doses.

Par challenged the patent’s ability to support the full scope of the method claims. The Federal Circuit upheld the district court’s judgment, rejecting the argument that the asserted claims failed the enablement requirement.

Infringement and ANDA labeling

In ANDA litigation, infringement may arise from the product itself, the proposed manufacturing process or the labeling submitted to FDA. A generic label that directs physicians or patients to use the product in a patented manner can support induced-infringement liability under 35 U.S.C. § 271(e)(2).

For Gilenya, the proposed product was designed to be therapeutically interchangeable with Novartis’s product. The legal risk therefore extended beyond the capsule formulation to the proposed use of fingolimod for multiple sclerosis at the claimed dosage.

How strong was Novartis’s Gilenya patent position after the decision?

The Federal Circuit ruling materially strengthened Novartis’s position against Par because it resolved core validity issues in favor of the patent holder. The decision reduced the likelihood that Par could obtain early entry by invalidating the '405 patent through the principal written-description and enablement theories presented on appeal.

Patent-strength assessment

Factor Assessment
Claim specificity Stronger than a broad genus claim because the dispute focused on a defined dose and treatment method
Written description Upheld against Par’s challenge
Enablement Upheld against Par’s challenge
ANDA litigation posture Favorable to Novartis
Generic substitution risk Dependent on the scope and expiration of remaining claims
Labeling risk Significant where proposed labeling directs the patented use
Parallel litigation risk Material because other ANDA applicants challenged related Gilenya rights

The decision did not convert every Gilenya patent into a permanent barrier. Patent strength remained claim-specific. An applicant could pursue a non-infringing label, challenge different patents, rely on an expired patent or negotiate a settlement with a licensed launch date.

What was the Orange Book status of Gilenya?

Gilenya’s Orange Book status depended on the patents listed by Novartis and the timing of FDA approval for each ANDA. The key legal distinction was between:

  • Drug-substance or composition patents.
  • Formulation and manufacturing patents.
  • Method-of-use patents.
  • Dosing-regimen patents.

A listed method-of-use patent may block FDA approval of an ANDA if the proposed labeling includes the patented indication or dosing instruction. Under the section viii procedure, an applicant may attempt to carve out the patented use where FDA permits a legally sufficient label omission. That route is less effective when the patented method corresponds closely to the principal approved indication or standard dosing regimen.

The Par case demonstrated the commercial value of a later-issued method patent. Even if earlier Gilenya compound rights were approaching expiration, the '405 patent presented a separate barrier tied to the approved therapeutic use.

Did the litigation involve biosimilar risk?

No. This was a small-molecule ANDA case, not a biosimilar case under the Biologics Price Competition and Innovation Act.

Fingolimod is a chemically synthesized small-molecule active ingredient. Generic competition proceeds through section 505(j) of the Federal Food, Drug, and Cosmetic Act. The relevant risks were Paragraph IV invalidity and non-infringement claims, label carve-outs, patent expiration and settlement terms.

Biosimilar concepts such as reference-product exclusivity, the 12-year biologics exclusivity period and the patent dance under 42 U.S.C. § 262(l) did not govern this action.

Which companies challenged Novartis’s Gilenya patents?

Par was one of several ANDA applicants involved in Gilenya patent disputes. The broader litigation landscape included generic manufacturers seeking approval for fingolimod products and challenging Novartis patents through Paragraph IV certifications.

The identity and timing of each challenger mattered because:

  • Each applicant could assert different invalidity grounds.
  • One applicant’s settlement could produce an earlier launch than another’s.
  • A judgment in one case could influence later litigation without automatically resolving every defendant’s claims.
  • A generic applicant could seek approval with a different label or formulation.

The Par decision was therefore relevant to the market’s overall generic-entry risk but did not necessarily determine the outcome of every separate Gilenya case.

Did Novartis and Par settle the case?

The reported Federal Circuit decision reflects appellate adjudication rather than a publicly controlling settlement outcome. The litigation reached a merits decision on the asserted patent, and the Federal Circuit affirmed the judgment favorable to Novartis.

A settlement could still affect commercial entry through a license, launch date, supply arrangement, royalty provision or authorized-generic commitment. Those terms are not established by the appellate opinion itself. The public judicial record establishes the patent judgment, not a commercial agreement that would supersede it.

What generic launch scenarios existed after the ruling?

The most important launch scenarios were:

Launch after patent expiry

Par could seek approval and commercial launch after expiration of the enforceable listed patents, subject to FDA approval and any pediatric exclusivity.

Non-infringing label

Par could attempt to remove the patented method from its labeling under a section viii statement. This strategy would depend on whether FDA accepted the carve-out and whether the resulting label avoided inducement liability.

Appeal or further validity challenge

Par could pursue available appellate or post-grant strategies, although the Federal Circuit decision reduced the viability of the theories rejected on appeal.

Settlement or license

Novartis and Par could agree to a negotiated entry date. A settlement could permit launch before the asserted patent’s nominal expiration while preserving the patent against other unlicensed entrants.

Authorized generic competition

Novartis could launch or license an authorized generic. That strategy could reduce the price premium available to an independent ANDA entrant even after legal market entry.

What was the commercial significance for Novartis?

Gilenya was a major Novartis product in the multiple sclerosis portfolio. The patent case protected revenue associated with the branded fingolimod product by preserving a later-expiring method-of-use patent against at least one generic challenger.

The financial effect of generic entry would depend on:

  • The actual timing of Par’s FDA approval.
  • The number of approved ANDA applicants.
  • Whether any applicant launched at risk.
  • The availability of authorized-generic supply.
  • The speed of substitution by payers and pharmacies.
  • The extent of price erosion.
  • The remaining life of other Gilenya patents and regulatory exclusivities.

A method patent tied to the standard dose can have greater commercial value than a narrow secondary formulation patent if the generic applicant’s proposed label necessarily includes the patented regimen.

How does this case compare with other Gilenya patent cases?

Novartis v. Par is best understood as a validity and infringement decision involving the standard fingolimod dose. Other Gilenya cases involved different defendants, patents and legal theories.

Issue Novartis v. Par Other Gilenya disputes
Product Fingolimod, Gilenya Fingolimod, Gilenya
Pathway ANDA ANDA
Principal patent issue 0.5 mg treatment method May involve composition, formulation or treatment claims
Key defenses Written description, enablement and infringement May include obviousness, anticipation or claim construction
Appellate outcome Judgment favorable to Novartis affirmed Must be assessed case by case
Commercial effect Delayed or complicated Par entry May establish different launch dates for other applicants

The Federal Circuit’s treatment of the '405 patent was important, but it did not eliminate the need for separate analysis of each patent, defendant and proposed label.

Key Takeaways

  • Novartis sued Par in Delaware after Par filed an ANDA with a Paragraph IV certification for generic fingolimod.
  • The litigation involved Gilenya and U.S. Patent No. 9,187,405.
  • The asserted patent protected a 0.5 mg daily fingolimod regimen for multiple sclerosis.
  • Par challenged the patent’s written description and enablement, among other issues.
  • The Federal Circuit affirmed the judgment favorable to Novartis in 2022.
  • The case was governed by the small-molecule ANDA framework, not the biosimilar pathway.
  • The ruling strengthened Novartis’s position against Par but did not resolve every Gilenya patent dispute.
  • Generic-entry timing remained dependent on patent expiration, FDA approval, label strategy, settlement terms and other ANDA applicants.

FAQs About Novartis v. Par Pharmaceutical and Gilenya

What was the civil action number for the Gilenya patent case?

The case was filed as Novartis Pharmaceuticals Corporation v. Par Pharmaceutical, Inc., No. 1:15-cv-00475, in the U.S. District Court for the District of Delaware.

Which Gilenya patent did Par challenge?

The central patent was U.S. Patent No. 9,187,405, directed to methods of treating multiple sclerosis using a 0.5 mg daily dose of fingolimod.

Did the Federal Circuit invalidate Novartis’s Gilenya patent?

No. The Federal Circuit affirmed the district court’s judgment favorable to Novartis in the Par litigation and rejected Par’s principal validity challenge.

Was Par’s generic fingolimod product a biosimilar?

No. Fingolimod is a small-molecule drug. Par’s product was pursued through an ANDA under section 505(j), not through the BPCIA biosimilar pathway.

Can a generic company avoid a Gilenya method patent by changing its label?

Potentially, if FDA accepts a legally sufficient section viii carve-out and the remaining label does not encourage the patented use. The feasibility depends on the specific claim, indication, dosage regimen and proposed labeling.

References

  1. Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(j).
  2. Hatch-Waxman Amendments, 21 U.S.C. § 355(j)(5)(B)(iii).
  3. Novartis Pharmaceuticals Corporation v. Par Pharmaceutical, Inc., 38 F.4th 1333 (Fed. Cir. 2022).
  4. U.S. Patent No. 9,187,405, United States Patent and Trademark Office.
  5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations [Orange Book].
  6. Biologics Price Competition and Innovation Act, 42 U.S.C. § 262(l).
  7. Patent Act, 35 U.S.C. §§ 112, 271(e)(2).

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.